EnPlusOne Biosciences, a Watertown, MA-based biotechnology company, raised $12M in Seed funding.
The round was led by Northpond Ventures with participation from Breakout Ventures, and Coatue.
The company intends to use the funds to build out its team and platform capabilities in line with the its mission to enable next-generation solutions for emerging RNA therapeutics.
Founded by George Church, PhD, Daniel Wiegand, Jonathan Rittichier, PhD, and Dan Ahlstedt as a technology spinout from the Wyss Institute for Biologically Inspired Engineering at Harvard University, EnPlusOne is a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides. It leverages an ezRNA synthesis platform that can incorporate a diverse array of nucleotide modifications to support direct RNA synthesis, and a vast array of RNA solution applications. The RNA synthesis platform aims to target synthesis lengths greater than 100-nt, large-scale GMP manufacturing, and novel therapeutic modifications in collaboration with industry partners.
FinSMEs
30/09/2022